At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 147 enrolled
Drug / intervention
riboflavin ophthalmic solution +1 moredrug
Likely dose
riboflavin ophthalmic solution 1.6 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Progressive Keratoconus
In Brief
A Phase 3 clinical trial evaluating riboflavin ophthalmic solution and UVA Irradiation for Progressive Keratoconus. Completed, enrolled 147 participants across 10 sites.
Detailed Summary
Prospective, randomized multicenter study to determine the safety and effectiveness of performing cornea collagen cross-linking (CXL) using riboflavin and UVA light in eyes with progressive keratoconus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProgressive Keratoconus
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedApr 2008
Primary CompletionApr 2011
TodayJul 2026
First PostedApr 1, 2008
Enrollment StartDec 1, 2007
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 18.3 years ago
Interventions
riboflavin ophthalmic solutiondrug
riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
UVA Irradiationdevice
UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes